The significant association between PI3K pathway alterations and poorer survival in NHW patients supports previous studies demonstrating that PI3K/AKT/mTOR signaling is a critical driver of tumor progression and therapy resistance in GC. This evidence concerns the gene AKT1 and neoplasm.